Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Posted byadmin 28. July 2020 Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, WeiГџmann A, Adam Z. http://www.ncbi.nlm.nih.gov/pubmed/24227817